Product Description
Mechanisms of Action: NK2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Depressive Disorder, Major|Generalized anxiety disorder|Depressive Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MC1952 | N/A |
Not yet recruiting |
Skin Cancer |
2017-10-01 |
|
| COMPASS | P3 |
Completed |
Depressive Disorder, Major |
2009-02-27 |
|
| COMPASS | P3 |
Completed |
Depressive Disorder, Major |
2009-02-01 |
|
| 2007-003159-36 | P3 |
Completed |
Depressive Disorder, Major |
2009-01-14 |